©The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 7, 2018; 24(33): 3677-3680
Published online Sep 7, 2018. doi: 10.3748/wjg.v24.i33.3677
Published online Sep 7, 2018. doi: 10.3748/wjg.v24.i33.3677
Time to think: Selecting patients who may benefit from synchronous resection of primary pancreatic cancer and liver metastases
Si Shi, Xian-Jun Yu, Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China
Si Shi, Xian-Jun Yu, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China
Si Shi, Xian-Jun Yu, Pancreatic Cancer Institute, Fudan University, Shanghai 200032, China
Author contributions: Shi S and Yu XJ conceived the study and drafted the manuscript; both authors approved the final version of the article.
Supported by the National Science Foundation for Distinguished Young Scholars of China , No. 81625016 ; and the Shanghai Sailing Program , No. 17YF1402500 .
Conflict-of-interest statement: The authors have no conflict of interest to declare.
Correspondence to: Xian-Jun Yu, MD, PhD, Professor, Surgeon, Surgical Oncologist, Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, No. 270 Dong'an Road, Xuhui District, Shanghai 200032, China. yuxianjun@fudanpci.org
Telephone: +86-21-64175590 Fax: +86-21-64031446
Received: June 16, 2018
Peer-review started: June 17, 2018
First decision: July 6, 2018
Revised: July 11, 2018
Accepted: July 22, 2018
Article in press: July 22, 2018
Published online: September 7, 2018
Processing time: 82 Days and 11.7 Hours
Peer-review started: June 17, 2018
First decision: July 6, 2018
Revised: July 11, 2018
Accepted: July 22, 2018
Article in press: July 22, 2018
Published online: September 7, 2018
Processing time: 82 Days and 11.7 Hours
Core Tip
Core tip: Pancreatic cancer patients with liver metastasis have worse prognoses than pancreatic cancer patients with metastasis at other sites. Improvement in the safety of pancreatic surgery has led to the consideration of more aggressive approaches. There is increasing agreement that synchronous resection of pancreatic cancer and liver metastases may selectively benefit some patients. A prospective multicenter, randomized, controlled phase three trial has been launched by the Chinese Study Group for Pancreatic Cancer with a goal of establishing such a selection strategy.